Parenteral nutrition-associated metabolic bone disease: Pathophysiology, evaluation, and treatment

Nutrition in Clinical Practice

Volumn 15, Issue 4, 2000, Pages 163-170

  Seidner, Douglas L ^a   Licata, Angelo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000416801     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/088453360001500402     Document Type: Review

References (38)

1. Marx SJ: Mineral and bone homeostasis. IN Cecil Textbook of Medicine, (20th ed.), Bennett JC, Plum F (Eds). W.B. Saunders, Philadelphia, 1996, pp 1351-1357.
2. Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. N Engl J Med 332:305-311, 1995.
3. Ravn P, Hetland ML, Overgaard K, et al: Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy x-ray absorptiometry. J Bone Miner Res 9:1975-1980, 1994.
4. Shike M, Harrison JE, Sturtridge WC, et al: Metabolic bone disease in patients receiving long-term TPN. Ann Intern Med 92:343-350, 1980.
5. Klein GL, Ament ME, Bluestone R, et al: Bone disease associated with TPN. Lancet 2:1041-1044, 1980.
6. Shike M, Shils ME, Heller A, et al: Bone disease in prolonged parenteral nutrition; Osteopenia without mineralization defect. Am J Clin Nutr 44:89-98, 1986.
7. Howard L, Heaphey L, Fleming CR, et al: Four years of North American registry home parenteral nutrition outcome data and their implications for patient management. JPEN 15:384-393, 1991.
8. Abitbol V, Roux C, Chaussade S, et al: Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 108:417-422, 1995.
9. Harvey HA: The management of hypercalcemia of malignancy. Supportive Care in Cancer 3:123-129, 1995.
10. Chu RC, Barkowski SM, Buhac J: Small bowel resection associated urinary calcium loss in rats on long-term TPN. JPEN 14:64-67, 1990.
11. Silvennoinen JA, Karttunen TJ, Niemela SE, et al: A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 37:71-76, 1995.
12. Reid IR: Glucocorticoid osteoporosis: Mechanisms and management. Eur J Endocrinol 137:209-217, 1997.
13. DeVernejoul MC, Messing B, Modrowski D, et al: Multifactorial low remodeling bone disease during cyclic TPN. J Clin Endocrinol Metab 60:109-113, 1985.
14. Zemel MB, Schuette SA, Hegsted M, et al: Role of sulfur-containing amino acids in protein-induced hypercalciuria in men. J Nutr 11:545-552, 1981.
15. DeFronzo RA, Cooke CR, Andes R, et al: The effect of insulin on renal handling of sodium, potassium, calcium and phosphorous in man. J Clin Invest 55:845-855, 1975.
16. Bengoa JM, Sitrin MD, Wood RJ, et al: Amino acid induced hypercalciuria in patients on TPN. Am J Clin Nutr 83:264-269, 1983.
17. Sloan GM, White DE, Brennan MF: Calcium and phosphorous metabolism during TPN. Ann Surg 197:1-6, 1983.
18. Wood RJ, Sitrin MD, Cusson GJ, et al: Reduction of TPN induced urinary calcium loss by increasing the phosphorous in the TPN prescription. JPEN 10:188-190, 1986.
19. Lau K, Goldfarb S, Goldberg M, et al: Effects of phosphate administration on tubular calcium transport. J Lab Clin Med 99:317-324, 1982.
20. Cunningham J, Fraher LJ, Clemens TL, et al: Chronic acidosis in metabolic bone disease: Effective alkali on bone density and vitamin D metabolism. Am J Med 73:199-204, 1982.
21. Karton MA, Rettmer R, Lipkin EW, et al: D-lactate and metabolic bone disease in patients receiving long-term parenteral nutrition. JPEN 13:132-135, 1989.
22. Wood RJ, Bengoa JM, Sitrin MD, et al: Calciuretic effect of cyclic versus continuous TPN. Am J Clin Nutr 41:614-619, 1985.
23. Lipkin EW, Ott SM, Chestnut CH, et al: Mineral loss in parenteral nutrition patients. Am J Clin Nutr 47:515-523, 1988.
24. Lipkin EW: A longitudinal study of calcium regulation in a nonhuman primate model of parenteral nutrition. Am J Clin Nutr 67:246-254, 1988.
25. Ott SM, Maloney NA, Klein GL, et al: Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med 99:910-914, 1983.
26. Goodman WG, Henry DA, Horst R, et al: Parenteral aluminum administration in the dog: II. Induction of osteomalacia and effect on vitamin D metabolism. Kidney Int 25:270-275, 1984.
27. Klein GL: Aluminum in parenteral products: Medical perspective on large and small volume parenterals. J Parenter Sci Technol 43:120. 1989.
28. Koo WWK, Kaplan LA, Horn J, et al: Aluminum in parenteral nutrition solutions: Sources and possible alternatives. JPEN 10:591-595, 1986.
29. Multivitamin preparations for parenteral use. A statement by the Nutrition Advisory Group. American Medical Association-Department of Foods and Nutrition, 1975. JPEN 3:258-262, 1979.
30. Shike M, Sturtridge WC, Tam CS, et al: A possible role of vitamin D in the genesis of parenteral nutrition induced metabolic bone disease. Ann Intern Med 95:560-568, 1981.
31. Seligman JV, Basi SS, Deitel M, et al: Metabolic bone disease in a patient on long-term TPN: A case report with review of literature. JPEN 8:722-727, 1984.
32. Vieth R: The mechanisms of vitamin D toxicity. Bone Miner 11:267-272, 1990.
33. Verhage, AH, Cheong WK, Allard JP, et al: Increase in lumbar spine bone mineral content in patients on long-term parenteral nutrition without Vitamin D supplementation. JPEN 19:431, 1995.
34. Hurley DL, Khosla S: Update on primary osteoporosis. Mayo Clin Proc 72:943-949, 1997.
35. Steiger ES, Seidner DL, McAdams MP, et al: Parenteral nutrition. IN The Cleveland Clinic Foundation: Nutrition Support Handbook, Matarese LM (Ed). The Cleveland Clinic Foundation, Cleveland, OH, 1997, pp 45-62.
36. Fleming CR, Georg L, Stoner GL, et al: The importance of urinary magnesium values in patients with gut failure. Mayo Clin Proc 71:21-24, 1996.
37. Administration of parenteral nutrition solutions. IN Handbook of TPN (2nd ed, Grant JP, Ed). W.B. Saunders, Philadelphia, 1992, pp 171-202.
38. Eastell R: Drug therapy: Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-746, 1998.